BioNTech's $1 Billion Buyback and the Race to Transform Into a Cancer Powerhouse

BioNTech starts $1B share repurchase while restructuring, slashing costs, and advancing cancer drugs; first FDA filing planned for 2026.

BioNTech kicked off a $1 billion share repurchase programme on the Nasdaq on 8 June, sending a clear signal of confidence even as it slashes costs and shrinks its footprint. The buy-and-hold strategy, managed by an independent bank and running until May 2027, comes alongside a brutal restructuring: the closure of manufacturing sites in Idar-Oberstein, Marburg, Tübingen and Singapore, with up to 1,860 jobs on the line. By 2029, the company expects to shave around €500 million from annual operating expenses.

The radical overhaul is necessary because the COVID-era revenue stream is drying up. In the first quarter of 2026, BioNTech booked just €118.1 million in sales, a fraction of its pandemic peak, and swung to a net loss of €531.9 million. Research and development spending hit €557 million. Still, a cash pile of approximately €16.8 billion provides a hefty safety net as the company burns through money to build an oncology franchise. Management is sticking to its full-year revenue forecast of €2.0–2.3 billion, but warns that cancer-related sales will not contribute until 2027 at the earliest.

The centrepiece of the oncology push is a first US filing with the FDA, planned for 2026 in partnership with DualityBio. The drug, Trastuzumab Pamirtecan (BNT323/DB-1303), targets advanced endometrial cancer and has already been granted Fast-Track and Breakthrough Therapy designations. A phase 2 trial of 145 patients showed a confirmed objective response rate of 47.9%, rising to 73.1% in those with the highest HER2 expression. Crucially, efficacy was observed across all HER2 expression levels, including low expression where no HER2-directed therapy is currently approved. In China, the NMPA has already accepted the application for review.

Beyond that filing, the second half of 2026 is packed with high-stakes data. BioNTech expects to release seven late-stage clinical data packages, including phase 3 results for Gotistobart in non-small cell lung cancer and a key interim analysis for the mRNA therapy BNT113 in HPV16-positive head and neck cancer with high PD-L1 expression. By the end of the year, the company plans to launch six additional phase 3 studies, bringing the total number of ongoing phase 3 programmes to 15. Over the past two years, the number of phase 2 and phase 3 oncology trials has more than doubled to over 25.

Recent data from the ASCO congress in Chicago underscored the breadth of the pipeline. Pumitamig combined with chemotherapy showed consistent antitumour activity in first-line non-small cell lung cancer — the third global data signal for that effect after earlier readouts in small cell lung cancer and triple-negative breast cancer. Gotistabart also demonstrated durable tumour activity in heavily pretreated patients with platinum-resistant ovarian cancer.

Wall Street remains broadly constructive but divided on the pace of the oncology turnaround. Morgan Stanley rates the stock Overweight with a $132 price target. Citigroup and Truist Financial maintain Buy ratings at $140 and $155 respectively. UBS upgraded to Buy in late May, setting a $135 target. Bernstein's Jeff Walch is more cautious, initiating coverage at Market Perform with a 12-month target of $96. The shares closed at €78.30 on Friday, down roughly 26% from the January high of €105.80 and just below the 50-day moving average. Over the past seven days the stock gained 5.6%. Whether the second half of the year delivers a lasting reversal depends largely on how convincing the phase 3 data for Gotistobart and BNT113 turn out to be.